Arcutis Cash And Short Term Investments from 2010 to 2024
ARQT Stock | USD 12.25 0.52 4.07% |
Cash And Short Term Investments | First Reported 2018-12-31 | Previous Quarter 363.1 M | Current Value 330.6 M | Quarterly Volatility 130.5 M |
Check Arcutis Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcutis Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 31.2 M, Selling General Administrative of 182.2 M or Total Revenue of 62.6 M, as well as many indicators such as Price To Sales Ratio of 3.57, Dividend Yield of 0.0 or PTB Ratio of 2.65. Arcutis financial statements analysis is a perfect complement when working with Arcutis Biotherapeutics Valuation or Volatility modules.
Arcutis | Cash And Short Term Investments |
Latest Arcutis Biotherapeutics' Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Arcutis Biotherapeutics over the last few years. Short Term Investments is an account in the current assets section of Arcutis Biotherapeutics balance sheet. This account contains Arcutis Biotherapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Arcutis Biotherapeutics fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Arcutis Biotherapeutics' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcutis Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
Timeline |
Arcutis Cash And Short Term Investments Regression Statistics
Arithmetic Mean | 117,970,698 | |
Geometric Mean | 23,071,085 | |
Coefficient Of Variation | 130.69 | |
Mean Deviation | 133,354,398 | |
Median | 3,418,000 | |
Standard Deviation | 154,174,694 | |
Sample Variance | 23769.8T | |
Range | 406.2M | |
R-Value | 0.82 | |
Mean Square Error | 8461.9T | |
R-Squared | 0.67 | |
Significance | 0.0002 | |
Slope | 28,206,665 | |
Total Sum of Squares | 332777.7T |
Arcutis Cash And Short Term Investments History
About Arcutis Biotherapeutics Financial Statements
Arcutis Biotherapeutics shareholders use historical fundamental indicators, such as Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Although Arcutis Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcutis Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcutis Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Cash And Short Term Investments | 271.9 M | 237.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.